Fat Loss

AOD 9604

Also known as: Advanced Obesity Drug 9604, HGH Fragment 177-191

RouteSubcutaneous

UK StatusAOD 9604 exists within a complex regulatory framework in the United Kingdom. The MHRA (Medicines and Healthcare products Regulatory Agency) has not licensed AOD 9604 as a medicine, and it lacks marketing authorisation for therapeutic use in the UK. The peptide is not classified as a prescription-only medicine (POM) under current MHRA regulations, nor is it listed as a controlled substance under the Misuse of Drugs Act 1971. Currently, AOD 9604 is primarily available through research chemical suppliers operating under 'not for human consumption' disclaimers. This represents the most common acquisition route for UK users, though it means quality control, purity, and pharmaceutical standards cannot be guaranteed according to MHRA requirements. Such suppliers operate in a regulatory grey area, and product quality can vary significantly. Some individuals import AOD 9604 from international suppliers where peptides may have different regulatory classifications. However, this approach carries potential customs risks and may involve importation of unlicensed medicines, which can be subject to seizure by UK Border Force. A limited number of UK compounding pharmacies may provide AOD 9604 under special circumstances, though availability varies significantly and typically requires medical oversight. Such arrangements may fall under 'specials' licensing provisions but remain uncommon. The Medicines Act 1968 technically covers any substance used for medicinal purposes in humans, creating potential legal considerations around personal use. However, enforcement typically focuses on commercial supply and marketing rather than individual possession for personal use. As of 2024, no specific regulatory changes have directly targeted AOD 9604, though increasing scrutiny of the research chemical market and peptide sector may affect future availability. The MHRA continues to monitor novel compounds and may issue guidance or restrictions as evidence emerges. Users should remain informed about potential regulatory developments and understand that using unlicensed compounds carries inherent risks regarding quality, purity, and legal status. For comprehensive information about UK peptide regulations and legal considerations, consult our detailed [UK peptide legality guide](/learn/uk-peptide-legality).

Overview

AOD 9604, officially known as HGH Fragment 177-191, represents one of the most targeted approaches to peptide-based fat loss available today. Developed in the late 1990s by Professor Frank Ng at Monash University, this 15-amino acid peptide fragment isolates the fat-burning properties of human growth hormone whilst eliminating the growth-promoting effects that make full-length HGH problematic for many users.

Unlike broad-spectrum fat loss peptides such as [Semaglutide](/peptides/semaglutide) or [Tirzepatide](/peptides/tirzepatide), AOD 9604 works through a highly specific mechanism. It targets β3-adrenergic receptors on fat cells, triggering lipolysis without affecting growth hormone pathways, insulin sensitivity, or glucose metabolism. This precision makes it a compound of particular interest to bodybuilders, fitness enthusiasts, and individuals seeking targeted abdominal fat reduction.

The peptide's clinical development included Phase II trials, with research suggesting consistent fat loss benefits compared to placebo over 12-week periods. What sets AOD 9604 apart is its preferential targeting of visceral abdominal fat—the metabolically active fat tissue that's notoriously difficult to lose through diet and exercise alone.

AOD 9604 occupies a unique position in the peptide landscape. Whilst [BPC-157](/peptides/bpc-157) focuses on healing and [CJC-1295](/peptides/cjc-1295) works through growth hormone release, AOD 9604 delivers direct lipolytic effects. Users often stack it with recovery peptides like [TB-500](/peptides/tb-500) during cutting phases, though it's equally effective as a standalone compound.

The peptide's appeal extends beyond the bodybuilding community. Clinical research participants were obese adults seeking sustainable weight management, and the results translate well to recreational users. However, AOD 9604 requires realistic expectations—it's not a miracle fat burner but rather a tool that enhances the effects of proper diet and exercise. Research participants reported improved body composition, reduced waist measurements, and better muscle definition over 12-24 week protocols.

For those considering AOD 9604, understanding proper [reconstitution](/learn/reconstitution-guide) and dosing is crucial, as is sourcing from reputable suppliers listed in our [supplier directory](/suppliers). The peptide's excellent safety profile from clinical trials makes it one of the lower-risk options in the peptide space, and our [peptide stacking guide](/learn/stacking-guide) provides detailed information on combining it with other compounds safely. Understanding [peptide storage](/learn/storage-guide) and [injection techniques](/learn/injection-guide) is also essential for optimal results.

Mechanism of Action

AOD 9604's mechanism represents precision engineering in peptide design. The fragment consists of amino acids 177-191 from human growth hormone's C-terminal region—specifically the portion responsible for lipolytic activity. By isolating these 15 amino acids, researchers eliminated growth hormone's anabolic and glucose-disrupting effects whilst preserving its fat-burning capabilities.

The peptide works primarily through β3-adrenergic receptor activation on adipocytes (fat cells). When AOD 9604 binds to these receptors, it triggers a cascade that increases cyclic adenosine monophosphate (cAMP) levels within the cell. Think of cAMP as the cellular 'go signal' for fat breakdown—elevated cAMP activates hormone-sensitive lipase, the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol that can be burned for energy.

Simultaneously, AOD 9604 inhibits lipogenesis—the process by which the body creates new fat stores. This dual action creates an optimal cellular environment for fat loss: enhanced breakdown of existing fat stores combined with reduced formation of new ones.

Research suggests that AOD 9604 demonstrates particular selectivity for abdominal fat deposits. Whilst the exact mechanism behind this selectivity isn't fully understood, studies indicate it may relate to the higher concentration of β3-adrenergic receptors in visceral adipose tissue compared to subcutaneous fat elsewhere in the body.

Unlike growth hormone-releasing peptides such as [Ipamorelin](/peptides/ipamorelin) or [Sermorelin](/peptides/sermorelin), AOD 9604 doesn't bind to growth hormone receptors. This explains its lack of growth-promoting effects and why it doesn't influence blood glucose levels or insulin sensitivity—common concerns with full-length growth hormone therapy.

Studies indicate that research participants experienced mild appetite suppression in some trials, though this appears to be a secondary effect rather than a primary mechanism. The peptide may influence satiety hormones or simply reduce cravings as body composition improves, creating a beneficial feedback loop that supports continued fat loss efforts throughout the treatment protocol.